Trial Profile
A placebo- and positive-controlled study of the electrophysiological effects of a single 10 microg dose of exenatide on the 12-lead electrocardiogram QT interval in healthy subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Exenatide (Primary) ; Moxifloxacin
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- Sponsors Amylin Pharmaceuticals
- 01 Oct 2008 Actual end date changed from 1 Aug 2008 to 1 Jul 2008 as reported by ClinicalTrials.gov.
- 01 Oct 2008 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 27 May 2008 New trial record.